4D Molecular Therapeutics (FDMT) Research & Development (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Research & Development data on file, last reported at $65.0 million in Q1 2026.

• On a quarterly basis, Research & Development rose 59.66% year-over-year to $65.0 million in Q1 2026; TTM through Mar 2026 was $220.0 million, a 42.72% increase from a year earlier, with the FY2025 full-year figure at $195.7 million, up 38.5% from the prior year.
• Research & Development for Q1 2026 stood at $65.0 million, up from $57.6 million in the prior quarter.
• Over the last five years, Research & Development for FDMT reached as high as $65.0 million in Q1 2026 and fell as low as $18.9 million in Q3 2022.
• Historically, Research & Development has averaged $34.1 million across 5 years, with a median of $27.9 million in 2024.
• Across the five-year window, Research & Development increased 15.48% in 2023 and surged 65.54% in 2024, its largest moves.
• Year by year, Research & Development stood at $21.5 million in 2022, then advanced by 21.06% to $26.0 million in 2023, then jumped by 65.54% to $43.1 million in 2024, then jumped by 33.7% to $57.6 million in 2025, then gained by 12.8% to $65.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $65.0 million in Q1 2026, $57.6 million in Q4 2025, and $49.4 million in Q3 2025.